Amylyx Pharmaceuticals, Inc.: Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026
Amylyx Pharmaceuticals (NASDAQ: AMLX) said it will present first-in-human, dose-ranging Phase 1 LUMINA trial data for AMX0114 at ENCALS 2026 (June 24-26, Madrid). In Cohort 1 (12.5 mg; n=12), the company reported no drug-related serious adverse events or serious neurological adverse events, and biomarker levels (SBDP-145, NfL, pNFH) stayed near baseline. Cohort 2 (25 mg) is fully enrolled; Cohort 3 (50 mg) is enrolling.
How this was made
The 30-second read
Why it matters
The newest concrete item is the Cohort 1 safety profile (no drug-related SAEs/serious neurological AEs) and the plan to continue evaluation at higher dose levels, which can modestly improve perceived clinical risk ahead of the ENCALS 2026 poster.
Market read
Traders may use the Cohort 1 safety datapoint to gauge near-term probability of continued dose escalation, but should wait for higher-dose cohort results for a more material re-rating.
What to watch
The release emphasizes safety and biomarker stability near baseline, but provides no efficacy endpoints or magnitude of biomarker change; funding/timeline risk remains a key overhang for preclinical/early clinical programs.
Background
Amylyx is running the LUMINA Phase 1 multiple-ascending-dose trial of AMX0114 (antisense oligonucleotide targeting calpain-2) in ALS; Cohorts 1 and 2 are fully enrolled and Cohort 3 is enrolling.
Ticker impact
Amylyx announced first-in-human LUMINA Phase 1 data for AMX0114, reporting no drug-related SAEs in Cohort 1 (12.5 mg).
Modest positive bias around the ENCALS 2026 presentation window; larger repricing likely only after higher-dose cohorts report.
The article discloses a concrete safety datapoint (no drug-related SAEs/serious neuro AEs at the lowest dose) and enrollment status (Cohort 3 enrolling), but it is still early-stage and lacks efficacy or higher-dose outcomes.
Market effects
Adds incremental confidence for ALS antisense oligonucleotide programs targeting neurodegeneration pathways, but without cross-company read-across.
Primarily US biotech sentiment; conference in Madrid may drive incremental European attention but no direct regional catalyst is specified.
Limited global impact beyond ALS clinical-trial risk sentiment; no regulatory or partnership developments mentioned.
Counterpoint
No drug-related SAEs at the lowest dose may not translate to safety at higher doses; the market may discount the signal until Cohort 2/3 higher-dose data are presented.
Key entities
- companyAmylyx Pharmaceuticals, Inc.
Sponsor of the AMX0114 LUMINA Phase 1 trial; presenting first-in-human dose-ranging safety data at ENCALS 2026.
- drug_candidateAMX0114
Investigational antisense oligonucleotide targeting calpain-2 in ALS; Cohort 1 safety results reported.
- clinical_trialLUMINA (NCT06665165)
Randomized, double-blind, placebo-controlled multiple ascending dose Phase 1 trial evaluating safety/tolerability and biomarkers.
- conferenceENCALS 2026
European Network to Cure ALS meeting where the poster presentation is scheduled June 24-26, 2026.
